-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

Benzinga·08/07/2026 17:14:09
Listen to the news
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.